TY - JOUR
T1 - Recognizing rare disorders
T2 - Aromatase deficiency
AU - Jones, Margaret E.E.
AU - Boon, Wah Chin
AU - McInnes, Kerry
AU - Maffei, Laura
AU - Carani, Cesare
AU - Simpson, Evan R.
N1 - © 2007 Springer Nature
PY - 2007/5/30
Y1 - 2007/5/30
N2 - Aromatase deficiency is rare in humans. Affected individuals cannot synthesize endogenous estrogens. Aromatase is the enzyme that catalyzes conversion of androgens into estrogens, and if aromatase is nonfunctional because of an inactivating mutation, estrogen synthesis cannot occur. If the fetus lacks aromatase activity, dehydroepiandrosterone sulfate produced by the fetal adrenal glands cannot be converted to estrogen by the placenta, so is converted to testosterone peripherally and results in virilization of both fetus and mother. Virilization manifests as pseudohermaphroditism in female infants, with hirsutism and acne in the mother; the maternal indicators resolve following delivery. To date, only seven males and seven females with aromatase deficiency have been reported. Affected females are typically diagnosed at birth because of the pseudohermaphroditism. Cystic ovaries and delayed bone maturation can occur during childhood and adolescence in these girls, who present at puberty with primary amenorrhea, failure of breast development, virilization, and hypergonadotrophic hypogonadism. Affected males, on the other hand, do not present with obvious defects at birth, so are diagnosed much later in life, presenting with clinical symptoms, which include tall stature, delayed skeletal maturation, delayed epiphyseal closure, bone pain, eunuchoid body proportions and excess adiposity. Estrogen replacement therapy reverses the symptoms in male and female patients.
AB - Aromatase deficiency is rare in humans. Affected individuals cannot synthesize endogenous estrogens. Aromatase is the enzyme that catalyzes conversion of androgens into estrogens, and if aromatase is nonfunctional because of an inactivating mutation, estrogen synthesis cannot occur. If the fetus lacks aromatase activity, dehydroepiandrosterone sulfate produced by the fetal adrenal glands cannot be converted to estrogen by the placenta, so is converted to testosterone peripherally and results in virilization of both fetus and mother. Virilization manifests as pseudohermaphroditism in female infants, with hirsutism and acne in the mother; the maternal indicators resolve following delivery. To date, only seven males and seven females with aromatase deficiency have been reported. Affected females are typically diagnosed at birth because of the pseudohermaphroditism. Cystic ovaries and delayed bone maturation can occur during childhood and adolescence in these girls, who present at puberty with primary amenorrhea, failure of breast development, virilization, and hypergonadotrophic hypogonadism. Affected males, on the other hand, do not present with obvious defects at birth, so are diagnosed much later in life, presenting with clinical symptoms, which include tall stature, delayed skeletal maturation, delayed epiphyseal closure, bone pain, eunuchoid body proportions and excess adiposity. Estrogen replacement therapy reverses the symptoms in male and female patients.
KW - Aromatase
KW - Dyslipidemia
KW - Estrogen
KW - Skeleton
KW - Testosterone
UR - http://www.scopus.com/inward/record.url?scp=34247516447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247516447&partnerID=8YFLogxK
U2 - 10.1038/ncpendmet0477
DO - 10.1038/ncpendmet0477
M3 - Review article
C2 - 17452968
AN - SCOPUS:34247516447
SN - 1745-8366
VL - 3
SP - 414
EP - 421
JO - Nature Clinical Practice Endocrinology and Metabolism
JF - Nature Clinical Practice Endocrinology and Metabolism
IS - 5
ER -